International — European Commission & European Union — European Medicines Agency

International — European Commission: The International — European Commission granted Etavopivat Orphan Drug designation, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Union — European Medicines Agency, which will facilitate its development and potential approval in Europe.

European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Orphan Medicinal Products provided a positive opinion for Etavopivat, leading to its Orphan Drug designation by the International — European Commission.